首页> 外国专利> PROBABILITY OF INJURY TO NORMAL TISSUES, ADAPTED WITH ACCOUNT OF MARKERS

PROBABILITY OF INJURY TO NORMAL TISSUES, ADAPTED WITH ACCOUNT OF MARKERS

机译:标记物适应的正常组织损伤可能性

摘要

FIELD: medicine.SUBSTANCE: group of inventions relates to medicine, oncology and deals with the formation of a patient's individual therapy plan. The method includes the formation of an initial plan of therapy by means of a normal tissue complication probability (NTCP) model and a tumour control probability (TCP) model for a target area. NTCP and TCP models are adapted on the basis of initial quantitative values of the patient's set of biomarkers. After the application of the initial therapy a corrected plan of therapy is formed by means of NTCP and TCP models, adapted on the basis of updated after the application of therapy quantitative values of the set of biomarkers. The initial and updated NTCP models are expressed in the form of the function of an equivalent uniform dose (EUD) modified with the application of a scalar value. The values of the set of biomarkers represent determined by an analysis values of parameters from the group: levels of Hb, CRP, PSA, TNF-?, ferritin, transferritin, LDH, IL-6, hepsidin, creatinine, glucose, HbA1c, complexes, binding DNA ends (DNA-EBC), HIF-l?, galectine-1, CAP43 and/or NDRG1; length of a telomere; type of the tumour; tumour degree; tumour stage; location of the initial tumour; degree of malignancy by the Gleason scale; data of the collagen level analysis; previous treatment in the form of abdominal surgery, hormonal drug therapy, anticoagulation drug therapy; presence of diabetes; patient's age. A machine-readable data carrier, which contains a programme, a controlling processor for carrying out the said method and a processor for carrying out method stages, is used.EFFECT: individual adaptive planning of therapy for an oncologic patient with the optimisation of a probability of injury to normal tissue and neutralisation of the tumour in accordance with the individual markers for each patient is provided.8 cl, 6 dwg
机译:领域:药物领域:一组发明涉及医学,肿瘤学,并涉及患者个体治疗计划的形成。该方法包括借助于正常组织并发症概率(NTCP)模型和针对目标区域的肿瘤控制概率(TCP)模型来形成治疗的初始计划。 NTCP和TCP模型根据患者生物标志物组的初始定量值进行调整。在应用初始疗法之后,借助于NTCP和TCP模型形成校正的疗法计划,该NTCP和TCP模型基于在应用疗法后生物标记集的定量值的更新而适应。初始和更新的NTCP模型以通过应用标量值修改的等效均等剂量(EUD)的函数形式表示。这组生物标志物的值由以下参数的分析值确定:血红蛋白,CRP,PSA,TNF-α,铁蛋白,转铁蛋白,LDH,IL-6,肝素,肌酐,葡萄糖,HbA1c,复合物的水平,结合DNA末端(DNA-EBC),HIF-1,半乳糖凝集素-1,CAP43和/或NDRG1;端粒的长度;肿瘤类型;肿瘤程度肿瘤分期初始肿瘤的位置;格里森量表的恶性程度;胶原蛋白水平分析数据;先前以腹部手术,激素药物疗法,抗凝药物疗法的形式进行治疗;糖尿病的存在;患者的年龄。使用一种机器可读的数据载体,其包含程序,用于执行所述方法的控制处理器和用于执行方法阶段的处理器。效果:针对肿瘤患者的个体适应性治疗计划,并优化其概率根据每个患者的个体标志物,对正常组织的损伤和肿瘤的中和作用进行了分析。8cl,6 dwg

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号